Calamos Advisors’s SpringWorks Therapeutics SWTX Stock Holding History

Calamos Advisors’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-7,650	Closed	-$288K	–	991
2024 Q2	$288K	Sell	7,650 -17,604	-70%	-$741K	﹤0.01%	752
2024 Q1	$1.24M	Buy	+25,254	New	+$1.17M	0.01%	624

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Calamos Advisors's SWTX Position: Q3 2024 in Review

Calamos Advisors sold out of SpringWorks Therapeutics (SWTX) in Q3 2024, closing a stake of 7,650 shares — an estimated $288K sold.

Calamos Advisors first reported a position in SWTX in Q1 2024 and held it in 2 quarters. The position peaked at $1.24M in Q1 2024. 226 funds tracked by Wall St. Rank hold SWTX as of Q3 2024.

Calamos Advisors reported no remaining SpringWorks Therapeutics position as of Q3 2024 after selling out during the quarter.
Calamos Advisors sold 7,650 SpringWorks Therapeutics shares in Q3 2024, an estimated $288K.
Calamos Advisors first reported a position in SpringWorks Therapeutics in Q1 2024 and held it in 2 quarters.
Calamos Advisors's SpringWorks Therapeutics position peaked at $1.24M in Q1 2024.
226 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2024.

Based on Calamos Advisors's 13F filing for Q3 2024, filed 7 Nov 2024.